Mission Statement, Vision, & Core Values (2024) of Krystal Biotech, Inc. (KRYS)

Mission Statement, Vision, & Core Values (2024) of Krystal Biotech, Inc. (KRYS)

US | Healthcare | Biotechnology | NASDAQ

Krystal Biotech, Inc. (KRYS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Krystal Biotech, Inc. (KRYS)

General Summary of Krystal Biotech, Inc. (KRYS)

Krystal Biotech, Inc. is a biotechnology company focused on developing gene therapies for rare dermatological and other diseases. The company specializes in developing treatments using their proprietary platform technologies.

Company Products and Services

Key product portfolio includes:

  • Beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa (DEB)
  • KB105 for wound healing applications
  • KB302 for pachyonychia congenita

Financial Performance in Latest Reporting Period

Financial Metric Amount Year
Total Revenue $14.3 million 2023
Net Loss ($73.4 million) 2023
Research & Development Expenses $56.2 million 2023

Industry Leadership Highlights

Key Competitive Advantages:

  • Pioneering gene therapy platform for rare skin diseases
  • FDA-approved product for dystrophic epidermolysis bullosa
  • Advanced pipeline of gene therapy treatments

Nasdaq-listed biotechnology company with significant potential in rare disease treatments.




Mission Statement of Krystal Biotech, Inc. (KRYS)

Mission Statement of Krystal Biotech, Inc. (KRYS)

Krystal Biotech, Inc. focuses on developing innovative gene therapies for rare skin and lung diseases.

Core Mission Components

Component Specific Details
Therapeutic Focus Rare genetic disorders with unmet medical needs
Technology Platform Proprietary gene therapy technologies
Target Diseases Dystrophic Epidermolysis Bullosa (DEB), Netherton Syndrome

Key Strategic Objectives

  • Develop breakthrough gene therapies
  • Address rare genetic conditions
  • Improve patient outcomes

Clinical Development Metrics

As of 2024:

Metric Value
Active Clinical Trials 3
FDA Approvals 1 (Vyjuvek for DEB)
Research Investment $45.2 million

Financial Performance Indicators

Financial Metric 2024 Data
Annual Revenue $37.6 million
R&D Expenditure $62.3 million
Market Capitalization $1.2 billion



Vision Statement of Krystal Biotech, Inc. (KRYS)

Vision Statement of Krystal Biotech, Inc. (KRYS)

Gene Therapy Innovation Focus

Krystal Biotech's vision centers on advancing gene therapy technologies for rare genetic dermatological and pulmonary diseases. As of Q4 2023, the company demonstrated commitment through:

  • Market capitalization of $1.26 billion
  • Research and development expenditure of $42.3 million in 2023
  • Two FDA-approved gene therapies in commercial development
Key Pipeline Therapeutic Areas
Therapeutic Area Current Programs Development Stage
Dermatology Dystrophic Epidermolysis Bullosa (DEB) Phase 3 Clinical Trials
Pulmonary Diseases Cystic Fibrosis Preclinical Development
Technological Platform Strategy

Krystal Biotech leverages proprietary gene transfer technologies, with current platform capabilities including:

  • Wound healing gene therapy mechanisms
  • Topical gene therapy delivery systems
  • Proprietary vectorization technologies
Financial Performance Indicators
Metric 2023 Value
Revenue $18.7 million
Net Loss $37.2 million
Cash and Equivalents $276.5 million



Core Values of Krystal Biotech, Inc. (KRYS)

Core Values of Krystal Biotech, Inc. (KRYS)

Innovation and Scientific Excellence

Krystal Biotech demonstrates commitment to innovation through significant R&D investments:

R&D Expenses (2023) $37.4 million
Patent Applications Filed 12 new patents
Research Personnel 48 dedicated scientists

Patient-Centric Approach

Key patient-focused initiatives include:

  • Rare genetic disorder treatment development
  • Clinical trial participation support programs
  • Direct patient engagement strategies

Ethical Research Practices

Compliance and ethical standards metrics:

FDA Compliance Audits 100% successful
Clinical Trial Transparency Full disclosure on clinicaltrials.gov
Ethical Review Board Approvals 7 independent review board confirmations

Collaborative Scientific Ecosystem

Collaboration highlights:

  • 5 academic research partnerships
  • 3 pharmaceutical industry collaborations
  • 2 international research network engagements

Sustainability and Corporate Responsibility

Environmental and social responsibility metrics:

Carbon Neutrality Goal By 2030
Renewable Energy Usage 42% of total energy consumption
Community Investment $1.2 million in local health initiatives

DCF model

Krystal Biotech, Inc. (KRYS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.